Clinical Trial Update: A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype. [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating BXCL701 in combination with pembrolizumab for metastatic castration-resistant prostate cancer with small cell neuroendocrine or ade…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Neuroendocrine Tumor
• Small Cell Carcinoma of the Prostate

Drugs mentioned

• BXCL701
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: BioXcel Therapeutics Inc | Conditions: Prostate Cancer, Neuroendocrine Tumors | Phase 1, Phase 2 | Status: COMPLETED